Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key opinion leaders discuss barriers to care for using CAR T-cell therapy for patients with large B-cell lymphoma, including time delays and lack of support for patients.
/PRNewswire/ -- The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2023" report has been added to...
Strong start for Omisirge® launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further... -Today at 07:02 am- MarketScreener
Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
Harry P. Erba, MD, PhD, discusses the implications of the FDA approval of quizartinib for the treatment of patients with FLT3-ITD–mutated AML, the background and key findings of the QuANTUM-First study, and how to now navigate between potential treatment options for this patient population.